Veradermics, Incorporated (MANE) compared with its closest peers (ABSI, CYPH, AKTS, DMAC, RLMD). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Absci: named a competitor in the 10-K.
| Company | Market Cap | P/E |
|---|---|---|
| Absci Corporation (ABSI) | $1.37B | -4.1 |
| Cypherpunk Technologies Inc. (CYPH) | $181.04M | 16.5 |
| Aktis Oncology, Inc. (AKTS) | $1.44B | — |
| DiaMedica Therapeutics Inc. (DMAC) | $364.54M | -11.4 |
| Relmada Therapeutics, Inc. (RLMD) | $477.25M | -3.3 |
| NRx Pharmaceuticals, Inc. (NRXP) | $149.37M | -2.0 |
| Oramed Pharmaceuticals Inc. (ORMP) | $210.48M | 4.1 |
| Sagimet Biosciences Inc. (SGMT) | $584.26M | -3.7 |
| PDS Biotechnology Corporation (PDSB) | $40.23M | — |
| Cocrystal Pharma, Inc. (COCP) | $22.25M | -1.2 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
MANE overview · MANE earnings · MANE financials · MANE KPIs · MANE documents · MANE ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.